NX Prenatal

What NX Prenatal does

NX Prenatal is a private molecular diagnostics company developing blood-based diagnostic assays for adverse pregnancy conditions, including spontaneous preterm birth, preeclampsia, and placenta accreta. Founded in 2013 and headquartered in Bellaire, TX (with offices in Lexington, KY and Louisville), the company operates with 1-10 employees and has raised approximately $10.7 million in total private funding. The company serves maternal-fetal medicine specialists, obstetricians, high-risk pregnant women, and academic medical centers conducting clinical research in maternal-fetal health.

The company's core technology is the proprietary NeXosome® exosome-based liquid biopsy platform, which enables advanced isolation and enrichment of exosome and microvesicle particles from maternal plasma for non-invasive biomarker evaluation. This platform underpins three flagship tests: Time2Prepare™ First Trimester Blood Test for predicting spontaneous preterm birth risk in nulliparous pregnant women (effective at weeks 9-13); a Preeclampsia Risk Assessment Test (effective at weeks 10-12, including molecular subtype identification distinguishing early-onset vs late-onset cases); and a Placenta Accreta Detection Test (83% accuracy at 24-26 weeks median). The platform is protected by 40+ issued and pending patents worldwide, with the company claiming the earliest and most comprehensive IP position for exosome-based pregnancy outcome detection. Clinical validation is supported by peer-reviewed publications in AJOG, Scientific Reports, and American Journal of Perinatology, with study data drawn from thousands of subjects across independent cohorts.

The business model centers on diagnostic assay development and commercialization via enterprise direct sales to healthcare systems and maternal-fetal medicine practices, supplemented by channel partnerships (Milu Labs for Asia commercialization, Thermo Fisher for LC-MS workflow integration) and platform licensing arrangements. The revenue stream is characterized as one-time licensing in nature, with the company still in clinical validation rather than full commercial launch. Recent leadership transitions in 2024 (new CEO Paul Kortschak and CFO Scott Gleason, both diagnostics industry veterans) and ongoing clinical study milestones suggest positioning for future commercial scaling, though the company currently has no disclosed revenue and remains pre-commercialization.

Name

NX Prenatal

Legal name

NX Prenatal Inc.

Website

https://nxprenatal.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

NX Prenatal is a private molecular diagnostics company developing proprietary NeXosome® exosome-based blood tests for early detection of adverse pregnancy conditions, including preterm birth, preeclampsia, and placenta accreta, serving maternal-fetal medicine specialists and high-risk pregnant women.

Ownership category

akta.pro rank

Product category

Prenatal Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genetic & Prenatal Testing Laboratories (HLAFAMAH), Maternal-Fetal Medicine (High-Risk Pregnancy) Centers (HLAFAJAB), Maternal-Fetal Medicine (High-Risk Pregnancy/Perinatology) (HLAKAJAB)

Keywords

• Prenatal molecular diagnostics
• Exosome liquid biopsy
• Maternal-fetal diagnostics
• Preterm birth screening
• Pregnancy biomarker tests

Headquarters

HQ city

Louisville

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Diagnostic Assay Development and Commercialization: NX Prenatal develops and commercializes molecular diagnostic assays for adverse pregnancy conditions including preterm birth, preeclampsia, and placenta accreta. The company utilizes its proprietary exosome-based platform to create blood-based diagnostic tests that are currently in clinical validation stage with peer-reviewed published studies demonstrating clinical utility.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

NX Prenatal develops and validates first-trimester maternal blood-based diagnostic tests for adverse pregnancy conditions — spontaneous preterm birth, preeclampsia, and placenta accreta — built on its proprietary NeXosome® exosome-based liquid biopsy platform. Tests are performed on a standard maternal blood sample collected during a routine office visit, providing risk stratification results as early as 9-13 weeks of gestation (10-14 weeks earlier than existing alternatives). The company is currently in clinical validation stage with peer-reviewed publications supporting its biomarker panels and intends to commercialize through laboratory service agreements and platform licensing with healthcare systems and channel partners.

Product overview

NX Prenatal is a molecular diagnostics company developing diagnostic assays for adverse pregnancy conditions including preterm birth, preeclampsia, and placenta accreta. The company's product portfolio centers on the proprietary NeXosome® exosome-based liquid biopsy platform, which enables advanced isolation and enrichment of exosome and microvesicle particles from maternal blood for non-invasive biomarker evaluation. The flagship Time2Prepare™ First Trimester Blood Test provides tailored maternal health information as early as weeks 9-13 of pregnancy through standard blood samples during regular office visits. Supporting products include Preeclampsia Risk Assessment (effective from weeks 10-12) and Placenta Accreta Detection (83% accuracy at 24-26 weeks). All tests leverage the core NeXosome® platform technology for biomarker discovery and validation.

Differentiator

Problem solved

Functional benefit

Brands

• Time2Prepare™: First-trimester blood test for predicting risk of spontaneous preterm birth among nulliparous pregnant women.
• NeXosome®

Products and services

• Time2Prepare™ First Trimester Blood Test First-trimester maternal blood test using the NeXosome® exosome-based liquid biopsy platform to predict spontaneous preterm birth risk as early as 9-13 weeks of pregnancy from a standard blood sample collected during a routine office visit. Targeted at nulliparous pregnant women and intended for use by maternal-fetal medicine specialists and OB/GYNs.
• Preeclampsia Risk Assessment Test First-trimester maternal blood test that uses circulating microparticle biomarkers from maternal plasma to assess preeclampsia risk as early as weeks 10-12 of pregnancy and to identify molecular subtypes distinguishing early-onset versus late-onset preeclampsia, enabling tailored maternal health strategies. Targeted at high-risk pregnant women including first-time mothers and those with prior preeclampsia history.
• Placenta Accreta Detection Test Maternal blood test using the NeXosome® exosome-based liquid biopsy platform to detect Placenta Accreta Spectrum cases from maternal plasma at a median 24-26 week time point with 83% accuracy, enabling mothers to schedule delivery with proper specialists to prevent life-threatening complications at birth.
• NeXosome® Liquid Biopsy Platform Proprietary exosome-based liquid biopsy platform that enables advanced isolation and enrichment of exosome and microvesicle particles from bodily fluids for non-invasive biomarker evaluation, providing real-time sampling of utero-placental and fetal-maternal crosstalk from early pregnancy via maternal plasma. Licensed as a standalone platform offering to channel/OEM partners within the maternal-fetal medicine field and integrated with Thermo Fisher LC-MS workflows for high-volume clinical proteomics.

Quantifiable outcome

• 83% accuracy in detecting Placenta Accreta cases from maternal plasma
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered flagship and core.

• Health Equity Innovation HubflagshipGTM or Marketing Partner · 16 February 2023Partnership to establish Alliance for Prenatal Health Equity. The Hub is a funded initiative of Humana Inc., the Humana Foundation, and the University of Louisville established to advance health equity and improve health outcomes for marginalized populations. NX Prenatal serves as founding member.
• Humana FoundationflagshipGTM or Marketing Partner · 5 January 2023Funder of Health Equity Innovation Hub supporting the Alliance for Prenatal Health Equity. The foundation's investment supports initiatives to advance health equity and improve health outcomes for marginalized populations in Louisville and communities around the world.
• Johnson & Johnson InnovationcoreGTM or Marketing Partner · 1 November 2022Maternal-Fetal Immune Disorders QuickFire Challenge: Innovating for Health Equity award. Award includes grant funding and mentorship from experts to help catalyze innovations directed toward the prevention of adverse pregnancy outcomes. Recognition for contributions to BIPOC maternal health.
• Thermo Fisher ScientificcoreTechnology or Integration · 5 April 2019Strategic collaboration designed to expand integrated workflows enabling high-volume clinical mass spec proteomic evaluation of plasma samples enriched for exosomes via the NeXosome® platform. Thermo Fisher's LC-MS instrumentation serves as enabling technology for personalized medicine applications.
• Milu LabscoreStrategic or Co-development Partner · 16 January 2019Strategic collaboration to commercialize exosome-based preterm birth risk test in Asia. Milu Labs' mission is to become the leading diagnostics company in Asia with a focus on maternal fetal medicine and women's health. NX Prenatal provides technology and tests while Milu Labs handles regional commercialization and distribution.
• Brigham & Women's HospitalcoreStrategic or Co-development PartnerOngoing and active research and clinical study collaborations. Brigham & Women's Hospital is a leading institution in maternal-fetal medicine, with Dr. Thomas McElrath serving on NX Prenatal's Advisory Board. Studies published in Scientific Reports demonstrate first trimester exosome liquid biopsy test data for preeclampsia risk.
• Indiana University School of MedicinecoreStrategic or Co-development PartnerClinical validation trial collaboration for exosome-based blood test for preterm birth risk. Partnership to further validate early pregnancy biomarker panels that predict Spontaneous Preterm Birth and to further develop biomarker panels for Preeclampsia.
• Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)coreStrategic or Co-development PartnerOngoing and active research and clinical study collaborations with NICHD, part of the National Institutes of Health, focused on maternal-fetal health research and adverse pregnancy outcomes.
• University of LouisvilleflagshipStrategic or Co-development PartnerFounding partner of Health Equity Innovation Hub alongside Humana and Humana Foundation. Established to advance health equity and improve health outcomes for marginalized populations through the Alliance for Prenatal Health Equity.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Roche Diagnostics: Roche Diagnostics is a global diagnostics giant with broad prenatal and women's health offerings, including NIPT through its acquisition of Ariosa and Genentech biomarkers. Comparable as a molecular diagnostics player in prenatal care, with substantially larger R&D, regulatory, and commercial capabilities.
• Myriad Genetics: Myriad Genetics is an established molecular diagnostics incumbent with a women's health franchise (including prenatal carrier screening through its Foresight product) and significant payor relationships. Comparable in that it sells biomarker-based diagnostic tests into the OB/GYN channel, though it is substantially larger and more diversified.
• Qiagen: Qiagen is a global molecular diagnostics and sample preparation technologies provider, with which NX Prenatal's CEO has prior executive experience. Comparable as a broad molecular diagnostics and life science tools incumbent, though with very different product focus and market positioning.
• LabCorp: LabCorp operates a major clinical laboratory network offering extensive prenatal testing services (including NIPT through its acquisition of Sequenom). Comparable in providing laboratory-based prenatal diagnostic services to healthcare providers, though at vastly larger scale and across many more diagnostic areas.
• Hologic: Hologic is a broad women's health diagnostics incumbent with established products in prenatal screening (e.g., the ACES platform), thin-prep cytology, and reproductive health. Comparable in target customers (OB/GYNs and maternal-fetal medicine practices) and women's health focus, though it operates across many more product categories.

Direct peers

• Natera: Natera is a major molecular diagnostics company offering a broad portfolio of prenatal and reproductive health tests including NIPT (Panorama) and women's health products. Both target the same maternal-fetal medicine channel with blood-based genetic and biomarker tests.
• Progenity: Progenity develops molecular diagnostics for women's health and prenatal care, including NIPT and pregnancy-related tests. While Progenity faced commercial headwinds, it represents a comparable operating model in prenatal molecular diagnostics targeting the same physician base.
• Sera Prognostics: Sera Prognostics is a direct peer developing blood-based diagnostic tests for preterm birth risk prediction, most notably the PreTRM® test. Both companies compete in the molecular prenatal diagnostics space targeting maternal-fetal medicine specialists and high-risk pregnant women with biomarker-based risk stratification.

Emerging players

• BillionToOne: BillionToOne is a high-growth molecular diagnostics company offering NIPT (Unity) and oncology liquid biopsy tests, with technology overlapping in the cell-free DNA and liquid biopsy domain. Comparable as an emerging molecular diagnostics player serving prenatal and women's health with novel biomarker approaches.

Others

• Thermo Fisher Scientific: Thermo Fisher Scientific is both a strategic collaborator and an enabler, providing LC-MS proteomic instrumentation that underpins the NeXosome® workflow. Comparable as a diagnostics-adjacent life sciences tools and clinical mass spectrometry provider, with substantial presence in clinical diagnostics and biopharma services.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/nxprenatal
• LinkedInlinkedin.com/company/nx-prenatal-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NX Prenatal